메뉴 건너뛰기




Volumn 39, Issue 8, 2016, Pages e123-e124

Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: A meta-analysis of randomized controlled trials

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

EID: 84980337086     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0885     Document Type: Letter
Times cited : (64)

References (15)
  • 1
    • 84864283226 scopus 로고    scopus 로고
    • SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects
    • Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8:495-502
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 495-502
    • Ferrannini, E.1    Solini, A.2
  • 2
    • 84962339296 scopus 로고    scopus 로고
    • Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition
    • Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38:1687-1693
    • (2015) Diabetes Care , vol.38 , pp. 1687-1693
    • Peters, A.L.1    Buschur, E.O.2    Buse, J.B.3    Cohan, P.4    Diner, J.C.5    Hirsch, I.B.6
  • 3
    • 84959366596 scopus 로고    scopus 로고
    • Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors
    • Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016; 7:135-138
    • (2016) J Diabetes Investig , vol.7 , pp. 135-138
    • Ogawa, W.1    Sakaguchi, K.2
  • 5
    • 84885954870 scopus 로고    scopus 로고
    • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial
    • Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1:208-219
    • (2013) Lancet Diabetes Endocrinol , vol.1 , pp. 208-219
    • Roden, M.1    Weng, J.2    Eilbracht, J.3
  • 6
    • 84888059660 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin inpatients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial
    • Wilding JPH, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin inpatients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67:1267-1282
    • (2013) Int J Clin Pract , vol.67 , pp. 1267-1282
    • Wilding, J.P.H.1    Charpentier, G.2    Hollander, P.3
  • 7
    • 84903511385 scopus 로고    scopus 로고
    • Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
    • Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37:1815-1823
    • (2014) Diabetes Care , vol.37 , pp. 1815-1823
    • Rosenstock, J.1    Jelaska, A.2    Frappin, G.3
  • 8
    • 84964240560 scopus 로고    scopus 로고
    • Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
    • Bode B, Stenlof K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17:294-303
    • (2015) Diabetes Obes Metab , vol.17 , pp. 294-303
    • Bode, B.1    Stenlof, K.2    Harris, S.3
  • 9
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 10
    • 84885952950 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
    • Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36:3396-3404
    • (2013) Diabetes Care , vol.36 , pp. 3396-3404
    • Häring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 11
    • 84887997289 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial
    • Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56:2582-2592
    • (2013) Diabetologia , vol.56 , pp. 2582-2592
    • Lavalle-González, F.J.1    Januszewicz, A.2    Davidson, J.3
  • 12
    • 84901455931 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
    • Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014; 37:1650-1659
    • (2014) Diabetes Care , vol.37 , pp. 1650-1659
    • Häring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 13
    • 84892477577 scopus 로고    scopus 로고
    • Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial
    • Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014; 16:147-158
    • (2014) Diabetes Obes Metab , vol.16 , pp. 147-158
    • Kovacs, C.S.1    Seshiah, V.2    Swallow, R.3
  • 14
    • 84942294658 scopus 로고    scopus 로고
    • Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial
    • Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015; 17:936-948
    • (2015) Diabetes Obes Metab , vol.17 , pp. 936-948
    • Rosenstock, J.1    Jelaska, A.2    Zeller, C.3    Kim, G.4    Broedl, U.C.5    Woerle, H.J.6
  • 15
    • 84962439093 scopus 로고    scopus 로고
    • Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors
    • Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: 1638-1642
    • (2015) Diabetes Care , vol.38 , pp. 1638-1642
    • Rosenstock, J.1    Ferrannini, E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.